Cas:53645-98-0 2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole manufacturer & supplier

We serve Chemical Name:2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole CAS:53645-98-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole

Chemical Name:2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole
CAS.NO:53645-98-0
Synonyms:2-chloro-5-(trifluoromethyl)-1,3,4-thiadiazole
Molecular Formula:C3ClF3N2S
Molecular Weight:188.55900
HS Code:2934999090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:54.02000
Exact Mass:187.94200
LogP:2.21030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-chloro-5-(trifluoromethyl)-1,3,4-thiadiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-chloro-5-(trifluoromethyl)-1,3,4-thiadiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-chloro-5-(trifluoromethyl)-1,3,4-thiadiazole Use and application,2-chloro-5-(trifluoromethyl)-1,3,4-thiadiazole technical grade,usp/ep/jp grade.


Related News: Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis. 2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole manufacturer Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole supplier ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole vendor The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances. 2-Chloro-5-trifluoromethyl-[1,3,4]-thiadiazole factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.